

Novel Complement Pathway Targets for the Treatment of Peripheral and Nervous System Inflammatory Disorders



Johnson & Johnson Innovation is interested in different elements of the **complement pathway** which could play a role in **inflammatory processes involved in systemic inflammation**, as well as in **diseases of the nervous system** with a neuroinflammatory component.

Targets of Interest

- Complement pathway, including CR1, C3, complement protein MASP and alternate complement pathway targets

Disease Areas of Interest

Johnson & Johnson Innovation is open to exploring opportunities to advance solutions in most diseases, with example areas including:

- Systemic inflammation e.g. rheumatology, autoimmunity, gastroenterology and immunodermatology
- Neuroinflammation e.g. Alzheimer's disease, Parkinson's disease, schizophrenia, major depressive disorder, Multiple Sclerosis, Amyotrophic Lateral Sclerosis and bipolar disorder

Therapeutic Modalities of Interest

Johnson & Johnson Innovation is open to all modalities, with a particular interest in small molecule and antibody approaches.

Development Stages of Interest

- Research at early stage through to phase I of clinical trials is within scope
- Research with validation, including human *ex vivo* data, and/or *in vivo* animal models, is of particular interest






Out of Scope

Complement C5-C9 and drug repurposing approaches are of lower interest

Submission Information & Potential Collaborations for Academics

- Submission of one page, 200-300 word briefs are encouraged. In submitting to this campaign, you confirm that your submission contains only non-confidential information
- Johnson & Johnson Innovation is open to a range of collaboration opportunities, with the most appropriate outcome being decided on a case-by-case basis. Example outcomes include licensing assets, project/PhD funding, and research collaborations

Opportunities sought

-  Technologies
-  Academics and expertise
-  Centres of excellence
-  Research projects
-  Spinout companies

Submissions

Please submit relevant, non-confidential opportunities online via: discover.in-part.com

Deadline: **4th October 2021 - 10:59 pm GMT**

Have any questions?

Contact our team at discover@in-part.co.uk

